Chrysos Corporation

The Business

Chrysos leases PhotonAssay units, a non-destructive X-ray technology that tests gold ore samples in minutes instead of the hours fire assay requires, to the world's four largest testing laboratories: ALS, SGS, Bureau Veritas and Intertek. It has 46 units deployed across 12 countries against 87 contracted units, meaning demand already exceeds current capacity. Revenue splits between a fixed lease fee (Minimum Monthly Assay Payment, 71% of revenue) and a usage-based fee tied to sample volumes and gold price. No competing technology exists or is in development.

Recent Performance

Revenue grew 33% to $88.1 million in FY26, building on 46% growth the year before, so the deceleration is real but the base is no longer small. EBITDA margin expanded from 24% to 31% as the fixed cost base absorbed higher volumes. The company posted its first statutory net profit, $1.8 million, in FY26. Despite this, only 7 new units were deployed against an 18-unit target, half the prior year's pace.

Outlook

Revenue growth is expected to decelerate over the next few years as the fleet expands from 46 to roughly double that number over five years. EBITDA margin should continue climbing as fixed central costs are spread across a larger fleet, a mechanical effect of the lease model rather than a hoped-for outcome. Earnings are expected to recover and grow substantially from the modest FY26 base, though the pace of that recovery depends heavily on deployment cadence holding above historical levels, something the company has not yet demonstrated it can sustain.

Our Valuation

We assess fair value using three independent methods: a discounted cash flow analysis, trading multiples benchmarked against capital equipment and technology-lessor comparables, and an asset-based floor. The debate over Chrysos's worth is less about the quality of the business, which is high, and more about the cost of capital the market should apply to a four-year-old listed company with a single-technology platform and a two-year history of missing its own deployment targets. The current price requires several favourable assumptions to hold simultaneously: a lower cost of capital than a business this young typically commands, deployment running faster than the company has ever achieved, and a terminal valuation multiple above typical capital equipment benchmarks.

Key Risks

Deployment execution is the largest swing factor. Chrysos has missed its own unit deployment target in each of the last two years, and sustained deployment below historical norms would meaningfully slow the revenue and margin trajectory the current growth story depends on. A reversion in gold price from current highs would compress the usage-based revenue stream, since that line surged on elevated gold prices during FY26 and carries genuine cyclical exposure. Longer term, the business depends on a single assay platform, and any competing technology reaching commercial scale, or a challenge to Chrysos's patent position, would represent a structural threat to the monopoly the current growth assumptions rely on. No such competitor exists today or is known to be in development, so this risk is longer-dated than the first two, but it carries the largest potential consequence if it materialises.

What to Watch

• 1-2 years Deployment acceleration — a sustained lift in the annual unit deployment count above recent history would be the clearest signal that fleet growth can outrun the FY26 shortfall.
• 1-3 years Market re-rating toward infrastructure-style cost of capital — if contracted revenue comes to be judged as reliable as toll-road cash flows, the market's view of appropriate risk could shift.

Company Description

Chrysos designs, manufactures and leases PhotonAssay units, an X-ray-based technology that measures gold (and other metal) content in ore samples without destroying them, unlike the traditional fire assay process. The company does not sell units outright; it earns recurring lease income (MMAP, 71% of revenue) plus a usage fee tied to sample throughput and gold price (AAC, the remainder). Its four lab partners, ALS, SGS, Bureau Veritas and Intertek, host the units and sell assay services to mining companies. The fleet spans 12 countries, with 46 units deployed against 87 contracted.

Where the Growth Is

Fleet deployment is the whole growth story. Contracted MMAP revenue already covers 71% of the top line, and the fleet is forecast to roughly double over five years, driving sustained double-digit revenue growth. Each new unit adds a largely fixed lease payment on top of an existing cost base, so the fleet expansion is expected to lift EBITDA meaningfully over five years as central costs are spread further across a larger installed base.

Competitive Position

Chrysos holds the only commercially deployed non-destructive bulk assay technology in the gold industry, built on more than 20 years of CSIRO research and protected by global patents. All four major assay laboratories have signed on as distribution partners, a structural advantage because switching an established lab relationship away from PhotonAssay would mean reverting to a slower, less accurate incumbent process. Market share of the addressable fleet opportunity (roughly 610 potential units globally) has risen from a low single-digit base to around 7%, and the runway to displace fire assay further remains long. No competitor technology exists in commercial or advanced development, and the moat looks to be widening rather than eroding.

Management & Capital Discipline

Management, led by founding chief executive Dirk Treasure, has funded fleet expansion through a mix of operating cash flow and a $140 million debt facility, a sensible approach for a business still in its build-out phase. Revenue guidance has been met consistently. The honest gap sits in operational delivery: deployment targets have been missed every year, with FY26 delivering just 7 units against an 18-unit target and down from 11 the year before. That combination, reliable financial forecasting but unreliable operational execution, is the single most important thing to watch.

Financial Position

Chrysos carries net debt of roughly 1.3 times EBITDA, comfortably within its facility limits, with $25.9 million of cash and an undrawn portion of its $140 million facility available. Free cash flow remains negative in the near term as growth capital expenditure outpaces earnings, but the trajectory points toward positive free cash flow within the next couple of years under current forecasts. The balance sheet can fund the current deployment plan without additional equity, though a sustained deployment shortfall would extend the timeline to positive free cash flow.